Updates at ASCO GU 2026
Enfortumab Vedotin Combo Boosts MIBC Survival Outcomes in EV-304 Trial

Data Show Comparable Immunotherapy Outcomes Across RCC Age Populations

Examining Pembrolizumab Combo Safety in High-Risk Prostate Cancer

Cabazitaxel Combo Does Not Significantly Improve Prostate Cancer Survival